-
Acute Abdomen in Adults- a Prospective Study on Emergency Department Admissions
This is a non-randomized, prospective, population-based, single-center study designed to evaluate conditions resulting emergency admission in patients with abdominal pain. Furthermore, we are interested in how many patients are discharged with "non-specific abdominal pain" but later readmitted and diagnosed with a specific diagnosis.
-
AMG 714 Expanded Access Program
Expanded access requests for AMG 714 may be considered for adult patients with biopsy proven Refractory Celiac Disease Type II who have failed all available treatment options and do not have EATL. To request access, use Responsible Party contact information provided in this record.
-
Anemia in Non-celiac Wheat Sensitivity
In recent years, a new gluten- or wheat-related disease has emerged, a condition labelled "non-celiac gluten sensitivity" (NCGS) or "non-celiac wheat sensitivity" (NCWS). This is very often a self-reported condition, since patients refer to intestinal [mainly irritable bowel syndrome (IBS)-like] and/or extra-intestinal symptoms (i.e. fatigue, headache, anemia) caused by gluten or wheat ingestion, even though they do not suffer from celiac disease (CD) or wheat allergy (WA). Among the extra-intestinal symptoms, several studies have shown, in patients with NCWS, the presence of anemia, generally mild, often with iron or folate...
-
Anti-Tissue Transglutaminase IgA Antibodies
Celiac disease is the most common genetically related food intolerance, worldwide. It is an immune mediated intolerance to gluten (from wheat, barley, or rye) in genetically susceptible individuals .The disease primarily affects the small intestine, where it progressively leads to flattening of the small intestinal mucosa .
-
A Pilot Study to Explore the Role of Gut Flora in Celiac Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Celiac Disease.
-
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
To assess the efficacy and safety of AGY vs placebo when administered to individuals age 10 to 65 years with medically proven CD and on a gluten free diet
-
Assessment of Adherence to Gluten Free Diet in Children and Adolescents by Detection of Gluten in Faecal Samples.
To assess the adherence to gluten free diet by measuring faecal and urinary gluten immunogenic peptides (GIP). This will provide an objective measure for adherence.
-
Assessment of KAN-101 in Celiac Disease (ACeD)
A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2. Part B - patients will receive three doses of either KAN-101 or placebo
-
Assess the Safety, Tolerability, Pharmacokinetics (PK), and Gluten Degradation Activity of PvP001, PvP002, and PvP003 in Healthy Adult Volunteers and to Assess the Safety, Tolerability, and PK of PvP001 and PvP002 in Adults With Celiac Disease (CeD)
The purpose of the study is to determine the safety and tolerability of single doses of PvP001 and PvP002, in healthy volunteers and participants with CeD in Part 1, to evaluate the ability of PvP001 and PvP002 to degrade gluten in healthy volunteers and to determine the effect of standard dose proton pump inhibitor (PPI) pretreatment on the ability of PvP001 to degrade gluten in healthy volunteers in Part 2, to evaluate the ability of PvP003 to degrade gluten in healthy volunteers in Part 3, and to determine the safety and tolerability of multiple doses of PvP003 600 milligram (mg), in healthy volunteers in Part 4.
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3915393 in Participants With Celiac Disease (CeD)
Celiac disease is a common T cell-mediated disorder triggered by dietary gluten with a worldwide prevalence estimated at one percent. GSK3915393 is being developed as an orally administered inhibitor of the enzyme transglutaminase 2 (TG2) for the treatment of participants with CeD. This study is the first time into human study (FTIH) for GSK3915393.
1 - 10 of 68 Trials
